Nandini Prashanth Bhat, Pugazhandhi Bakthavatchalam, Hareesh Krishnan, Ashwija Shetty, Prasanna Lokadolalu Chandracharya
Nandini Prashanth Bhat1, Pugazhandhi Bakthavatchalam2, Hareesh Krishnan3, Ashwija Shetty1, Prasanna Lokadolalu Chandracharya1*
1Department of Anatomy, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Karnataka, India.
2Department of Anatomy, Melaka Manipal Medical College (Manipal Campus), Manipal Academy of Higher Education, Karnataka, India.
3Medical Officer [Homoeopathy], Govt Homoeo Dispensary, Melur - PO, Kannur.
Volume - 14,
Issue - 9,
Year - 2021
Background: Generalized anxiety disorder (GAD) and depression are the common mental health diseases affecting millions of people globally. The conventional treatment with medications causes a lot of adverse effects leading patients to seek relief from alternative systems of medicine. The alternative mode of treatment, Homeopathy, uses ultra-diluted drugs to treat GAD and Depression. Objective: This review is to narrate and assess the effectiveness of homeopathy in anxiety and depressive disorders. Also, the related animal studies and in-vitro studies have been evaluated. Methods: The search used combinations of Medical Subject Heading terms ultra-diluted, anxiety, and depression. Lists of articles under references were reviewed to identify additional studies. Results: Studies suggest that ultra diluted, dynamised medicines are used by homeopathic practitioners to treat anxiety and depression. Homeopathic physicians prescribe individualized drugs after a detailed case taking. These have a favorable effect on the patients compared to control and also to conventional medicines. In- vivo studies show encouraging results as ultra- diluted drugs act as anxiolytics without altering the motor abilities of the animal models. In-vitro studies are lacking to reach a decisive inference. Conclusion: Although there are enough preliminary studies establishing proof of the effect of homeopathy in mental health ailments, further exploration is essential and ought to embrace well premeditated controlled studies with sufficient sums of participants.
Cite this article:
Nandini Prashanth Bhat, Pugazhandhi Bakthavatchalam, Hareesh Krishnan, Ashwija Shetty, Prasanna Lokadolalu Chandracharya. Effect of Ultra-diluted Medicines in Depression and Anxiety: A Narrative Review. Research Journal of Pharmacy and Technology. 2021; 14(9):5059-4. doi: 10.52711/0974-360X.2021.00882
Nandini Prashanth Bhat, Pugazhandhi Bakthavatchalam, Hareesh Krishnan, Ashwija Shetty, Prasanna Lokadolalu Chandracharya. Effect of Ultra-diluted Medicines in Depression and Anxiety: A Narrative Review. Research Journal of Pharmacy and Technology. 2021; 14(9):5059-4. doi: 10.52711/0974-360X.2021.00882 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-96
2. Bandelow B and Michaelis S. Epidemiology of Anxiety Disorders in the 21st Century. Dialogues in Clinical Neuroscience. 2015;17 327-335.
3. Raju V, Bell JJ, Merlin. NJ et.al Anxiety Disorders – A Review. Asian Journal of Pharmacology and Research. 2017; 7(4): 217-221.doi: 10.5958/2231-5691.2017.00033.8
4. Baxter A, Scott K, Vos T et.al. Global Prevalence of Anxiety Disorders: A Systematic Review and Meta-regression. Psychological Medicine. 2012; 43: 897-910.
5. Hirschfeld RM. The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. Primary Care Companion to the Journal of Clinical Psychiatry. 2001;3(6):244‐254. doi:10.4088/pcc.v03n0609
6. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, fifth edition, American psychiatric publishing.
7. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiologia e Psichiatria Sociale. 2009;18(1):23‐33. doi:10.1017/s1121189x00001421.
8. Mahadik PS, Senthilkumar GP, Powar AS, et.al. Chemical and Biological Properties of Benzodiazepines- An overview. Research Journal of Pharmacy and Technology. 2012;5(2):181-189.
9. Patel MA, Patel CM, Patel DB, et.al. A Review on Novel Strategies for Pharmacotherapy of Depression. Research Journal of Pharmacology and Pharmacodynamics. 2010;2(2):153-159.
10. Tiller J. Depression and Anxiety. The Medical Journal of Australia. 2012; 1: 28-31.
11. Bhagat V, Symbak NB, Husain R, et.al. The role of selective serotonin reuptake inhibitors and cognitive behavioral therapy in preventing relapse of Major Depressive Disorder. Research Journal of Pharmacology and Technology 2019;12(8):3818-3824.
12. Locke A, Kirst N and Shultz C. Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults. American Family Physician. 2015; 91: 617-624.
13. Jackson C. Trends in the Use of Complementary Health Approaches Among Adults in the United States. Holistic Nursing Practice. 2015; 29(3): 178-179.
14. Aswathi T, Venkateswaramurthy N and Kumar SR. A Review on Relevance of Herbal Medications for Psychiatric Patients. Research Journal of Pharmacy and Technology. 2019; 12(7): 3151-3156. doi 10.5958/0974-360X.2019.00531.6
15. Dossett ML, Davis RB, Kaptchuk TJ et.al. Homeopathy Use by US Adults: Results of a National Survey. American Journal of Public Health. 2016; 106(4): 743–745. doi: 10.2105/AJPH.2015.303025
16. Balaji DP. ADHD for Children in Homeopathy and Alternative Methdos. Research Journal of Humanities and Social Sciences. 2017; 8(2): 205-209.
17. Grolleau A, Bégaud B and Verdoux H. Characteristics associated with use of homeopathic drugs for psychiatric symptoms in the general population European Psychiatry. 2013; 28(2): 110-6. doi: 10.1016/j.eurpsy.2011.10.005. Epub 2011 Dec
18. Fisher P. What is Homeopathy an Introduction. Frontiers in Bioscience. 2012; E4: 1669-1682.
19. Brien S, Lewith G and Bryant T. Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C [published correction appears in Br J Clin Pharmacol. 2004;57(1):117]. British Journal of Clinical Pharmacology. 2003; 56(5): 562–568. doi:10.1046/j.1365-2125.2003.01900.x
20. Relton C, Cooper K, Viksveen P et.al. Prevalence of homeopathy use by the general population worldwide: a systematic review. Homeopathy. 2017; 106(2):69-78. doi: 10.1016/j.homp.2017.03.002.
21. Kent JT. The Art and Science of Homeopathic Medicine. New York: Dover Publications; 2002
22. Jonas WB, Kaptchuk TJ and Linde K. A critical overview of homeopathy. Annals of Internal Medicine. 2003; 138(5): 393-9.
23. Betti L, Trebbi G, Olioso D, et.al. Basic research in homeopathy and ultra-high dilutions: what progress is being made? Homeopathy. 2013; 102(2):151-4. doi: 10.1016/j.homp.2013.01.002.
24. Almirantis Y and Tsitinidis K. Ultra-High Dilutions and Homeopathy: Can They Be Explained without Non-Local Theory? Homeopathy. 2018;107(3):189-195. doi: 10.1055/s-0038-1656513.
25. Viksveen P, Relton C and Nicholl J. Depressed patients treated by homeopaths: a randomised controlled trial using the “cohort multiple randomised controlled trial” (cmRCT) design. Trials. 2017;18(1). doi: 10.1186/s13063-017-2040-2
26. Davidson JR, Morrison RM, Shore J, et.al. Homeopathic treatment of depression and anxiety. Alternative Therapies in Health and Medicine. 1997; 3(1): 46-9.
27. Bagherian M, Mojembari AK and Hakami M. The Effects of Homeopathic Medicines on Reducing the Symptoms of Anxiety and Depression: Randomized, Double Blind and Placebo Controlled. Journal of Homeopathic and Ayurvedic Medicine. 2015; 03 (04). doi: 10.4172/2167-1206.1000167
28. Grimaldi-Bensouda L, Abenhaim L, Massol J, et. al. Homeopathic Medical Practice for Anxiety and Depression in Primary Care: The EPI3 Cohort Study. BMC Complementary and Alternative Medicine. 2016; 16: 1-9.
29. Cialdella P, Boissel JP, Belon P; Groupe de recherche ASTRHO. Spécialités homéopathiques en substitution de benzodiazépines: étude en double-insu vs. placebo [Homeopathic specialties as substitutes for benzodiazepines: double-blind vs. placebo study]. Therapie. 2001; 56(4): 397‐402.
30. Wasilewski BW. Homeopathic remedies as placebo alternatives--verification on the example of treatment of menopause-related vegetative and emotional disturbances. Science and Engineering Ethics. 2004;10(1):179‐188. doi:10.1007/s11948-004-0075-8
31. Bonne O, Shemer Y, Gorali Y, et.al. A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. Journal of Clinical Psychiatry. 2003; 64(3): 282-7.
32. Van den Meerschaut L and Sünder A. The homeopathic preparation Nervoheel N can offer an alternative to lorazepam therapy for mild nervous disorders. Evidence Based Complementary and Alternative Medicine. 2009; 6(4): 507‐515. doi:10.1093/ecam/nem144
33. Hart P, Bergner C, Smolinsky A, et. al. Experimental Models of Anxiety for Drug Discovery and Brain Research. Methods in Molecular Biology. 2009;299-321. doi: 10.1007/978-1-60761-058-8_18
34. Ghaisas MM, Wadikar AD, Gulati TB, et.al. Anxiolytic Effect of a Methanolic Extract of the Embelia ribes Burm F. in Mice. Research Journal of Pharmacy and Technology. 2010; 3(4): 1136-1139.
35. Venkatesha G, Kalaiyarasia C and Ramanathana M. Antidepressant like Effect of Gabapentin Decreases the Immobility Time in Despair Animal Models in Mice: Roll of Serotonergic System in it. Research Journal of Pharmacy and Technology. 2011; 4(11): 1702-1706.
36. Bellavite P, Conforti A, Marzotto M, et. al. Testing Homeopathy in Mouse Emotional Response Models: Pooled Data Analysis of Two Series of Studies. Evidence-Based Complementary and Alternative Medicine. 2012; 2012: 1-9.
37. Prabhu R, Ruckmani A, Venkatesan D, et.al. Anxiolytic Effect of Homeopathic Preparation of Pulsatilla Nigricans in Swiss Albino Mice. Homeopathy. 2012; 101: 171-174.
38. Anser H, Najam R, Khatoon H, et.al. Evaluation of Anxiolytic Activity of Homeopathic Remedy Argentum Nitricum of 30 C Potency after Chronic Administration in Rodents. International Journal of Pharmaceutical Sciences and Research. 2018; 9: 3908-3913.
39. Haine, GB, Ghandour SH, Ghandour SA, et.al. Assessment of homeopathic medicine Aconitum napellus in the treatment of anxiety in an animal model. International Journal of High Dilution Research. 2012; 11(38): 33-42
40. Soliman MA, Aboharb F, Zeltner N, et.al. Pluripotent stem cells in neuropsychiatric disorders. Molecular Psychiatry. 2017; 22: 1241-1249.
41. Ramboz S, Oosting R, Amara DA, et.al. Serotonin receptor 1A knockout: An animal model of anxiety-related disorder. Proceedings of the National Academy of Sciences. 1998;95(24):14476-14481. doi:10.1073/pnas.95.24.14476
42. Rey AA, Purrio M, Viveros M et.al. Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission. Neuropsychopharmacology. 2012; 37(12):2624-2634. doi:10.1038/npp.2012.123
43. Lydiard RB. The role of GABA in Anxiety Disorders. The Journal of Clinical Psychiatry. 2003;64: 21-27.
44. Kita A, Kohayakawa H, Kinoshita T, et.al. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. British Journal of Pharmacology. 2004;142(7): 1059-1072. doi:10.1038/sj.bjp.0705681
45. Khose RD, Jaydeokar AV, Patil US, et.al. Receptor Pharmacology of GABA: A Review. Research J. Pharm. and Tech. 2012; 5(6): 721-728.
46. Heldt SA, Mou L and Ressler KJ. In vivo knockdown of GAD67 in the amygdala disrupts fear extinction and the anxiolytic-like effect of diazepam in mice. Translational Psychiatry. 2012; 2(11). doi:10.1038/tp.2012.101
47. Tan KR, Rudolph U, and Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends in Neurosciences. 2011;34(4): 188–197. doi: 10.1016/j.tins.2011.01.004
48. Marzotto M, Olioso D, Brizzi M, et.al. Extreme Sensitivity of Gene Expression in Human SH-SY5Y Neurocytes to Ultra-low doses of Gelsemium Sempervirens. BMC Complementary and Alternative Medicine. 2014; 14: 1-9.